The STING inhibitor (ISD-017) reduces glomerulonephritis in 129.B6.Fcgr2b-deficient mice

Isara Alee,Papasara Chantawichitwong,Asada Leelahavanichkul,Søren R. Paludan,Trairak Pisitkun,Prapaporn Pisitkun
DOI: https://doi.org/10.1038/s41598-024-61597-z
IF: 4.6
2024-05-15
Scientific Reports
Abstract:The absence of stimulator of interferon genes (STING) in 129.B6. Fcgr2b -deficient mice rescue lupus phenotypes. The administration of a STING inhibitor (ISD017) into the young 129.B6. Fcgr2b -deficient mice prevents lupus nephritis development. This study mainly aimed to evaluate the effects of STING inhibition (ISD107) on established SLE in mice to prove that ISD017 could be a good therapeutic drug to reverse the already set-up autoimmunity and kidney impairment. Twenty-four-week-old Fcgr2b -deficient mice were treated with cyclophosphamide (25 mg/kg, intraperitoneal, once per week), ISD017 (10 mg/kg, intraperitoneal, three times per week), or control vehicle for 8 weeks, and were analyzed for phenotypes. Both ISD017 and cyclophosphamide treatment increased long-term survival and reduced the severity of glomerulonephritis in Fcgr2b -deficient mice. While cyclophosphamide reduced activated B cells (B220 + GL-7 + ), ISD017 decreased activated T cells (CD4 + CD69 + ) and neutrophils (Ly6c + Ly6g + ) in Fcgr2b -deficient mice. In addition, ISD017 reduced IL-1β and interferon-inducible genes. In summary, ISD017 treatment in symptomatic 129.B6. Fcgr2b -deficient mice reduced the severity of glomerulonephritis and increased long-term survival. ISD017 worked comparably to cyclophosphamide for treating lupus nephritis in 129.B6. Fcgr2b -deficient mice. ISD017 reduced activated T cells and neutrophils, while cyclophosphamide targeted activated B cells. These results suggested that STING inhibitors can potentially be a new therapeutic drug for treating lupus.
multidisciplinary sciences
What problem does this paper attempt to address?